Abstract
Lymphoma treatment has been shown to be associated with increased risk of atrial fibrillation (AF), especially among patients treated with Bruton Tyrosine Kinase inhibitors (BTKi). However, there are limited data on the risk of new onset AF during lymphoma treatment among patients without a prior history of AF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
